2. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022. 3. Narin Ozturk, Dilek Ozturk Civelek, et al. "Dosing-time dependent testicular toxicity of everolimus in mice." Eur J Pharm Sci. 2021 Oct 1;165:...
2. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022. 3. Narin Ozturk, Dilek Ozturk Civelek, et al. "Dosing-time dependent testicular toxicity of everolimus in mice." Eur J Pharm Sci. 2021 Oct 1;165:...
"In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022. 3. Narin Ozturk, Dilek Ozturk Civelek, et al. "Dosing-time dependent testicular toxicity of everolimus in mice." Eur J Pharm Sci. 2021 Oct 1;165:105926. PMID: 34242751...
RAD001istheexperimentaldrug(mTORinhibitor),LY294002isthecontroldrug (PI3Kinhibitors).Experimentisdividedintoblankcontrolgroup,RAD001group, LY294002groupandthetwodrugcombinationgroup.Drugafter24hoursusing MTTassayinhibitoryrateofcellsineachgroup,andcalculatethecombinationindex ...
mTOR inhibitor;pancreatic cance r;drug resista nce ;c-Raf signaling pathway 胰腺癌是常见的消化道系统恶性肿瘤 ,发病隐匿, 手术切除率低 ,且传统放化疗效果差 ,因此寻求有效的 靶向药物是提高胰腺癌治疗的关键 。哺乳动物雷帕 霉素靶蛋 白 (mammalian target of rapamycin,mTOR) ...
The ubiquitin-proteasome and the Akt/mammalian target of rapamycin (mTOR) pathways are examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib (a small molecule protease inhibitor) and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of...
However, chronic drug exposure may trig... I Tsaur,J Makarevi?,E Juengel,... - 《British Journal of Cancer》 被引量: 91发表: 2012年 基于mTOR通路及细胞自噬的红景天苷保护受损PC12细胞的分子机制研究 1α和REDD1的表达升高,mTOR和p70S6K磷酸化水平降低,而红景天苷能够下调HIF-1α和REDD1的表达并...
Everolimus, an immunosuppressive drug widely used for the prevention of allograft rejection and an mTOR inhibitor, is one of the latest drugs undergoing clinical trials in metastatic renal cell carcinoma. It has been tested in patients with progressive disease after therapy with tyrosine kinase ...
Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions. J Clin Invest. 2009;119:1727–40. Article CAS Google Scholar Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3K and KRAS signaling pathways ...
However, drug-related cumulative toxicity, unresponsiveness to docetaxel therapy, and the development of resistance limit its clinical benefits3,4,5. Many tumour cells express vascular endothelial growth factor (VEGF) as a principal regulator of angiogenesis. VEGF induces proliferation of endothelial ...